Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: A randomised controlled clinical trial

Heart

Volumn 97, Issue 19, 2011, Pages 1560-1565

  Ludman, Andrew J ^a   Yellon, Derek M ^a   Hasleton, Jonathan ^a   Ariti, Cono ^b   Babu, Girish Ganesha ^a   Boston Griffiths, Edney ^a   Venugopal, Vinod ^a   Walker, Malcolm ^c   Holdright, Diana ^c   Swanton, Howard ^c   Crake, Tom ^c   Brull, David ^c   Moon, James C ^c   Puranik, Rajesh ^d   Mutharangu, Vivek ^d   Taylor, Andrew ^d   Hausenloy, Derek J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE MB; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TROPONIN T;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CORONARY CIRCULATION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INJECTIONS, INTRAVENOUS; LONDON; MAGNETIC RESONANCE IMAGING; MALE; MICROCIRCULATION; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; PLACEBO EFFECT; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; TROPONIN T; VENTRICULAR FUNCTION, LEFT;

EID: 80052666905     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2011.223867     Document Type: Article

References (30)

1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357:1121-35.
2. Riksen NP, Hausenloy DJ, Yellon DM. Erythropoietin: ready for prime-time cardioprotection. Trends Pharmacol Sci 2008;29:258-67.
3. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505. (Pubitemid 36337492)
4. Lipsic E, van der MP, Voors AA, et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006;20:135-41.
5. Ortiz-Perez JT, Meyers SN, Lee DC, et al. Angiographic estimates of myocardium at risk during acute myocardial infarction: validation study using cardiac magnetic resonance imaging. Eur Heart J 2007;28:1750-8. (Pubitemid 47227100)
6. Wright J, Adriaenssens T, Dymarkowski S, et al. Quantification of myocardial area at risk with T2-weighted CMR: comparison with contrast-enhanced CMR and coronary angiography. JACC Cardiovasc Imaging 2009;2:825-31.
7. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation 2005;112:2143-8. (Pubitemid 41475808)
8. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473-81.
9. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998;97:765-72. (Pubitemid 28135339)
10. Hombach V, Grebe O, Merkle N, et al. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J 2005;26:549-57. (Pubitemid 40461096)
11. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the 'no reflow'phenomenon. A predictor of complications and left ventricular remodelling in reperfused anterior wall myocardial infarction. Circulation 1996;93:223-8. (Pubitemid 26031478)
12. Bogaert J, Kalantzi M, Rademakers FE, et al. Determinants and impact of microvascular obstruction in successfully reperfused ST-segment elevation myocardial infarction. Assessment by magnetic resonance imaging. Eur Radiol 2007;17:2572-80.
13. Lee CH, Tse HF. Microvascular obstruction after percutaneous coronary intervention. Catheter Cardiovasc Interv 2009;75:369-77.
14. Lippi G, Franchini M, Favaloro EJ. Thrombotic complications of erythropoiesis-stimulating agents. Semin Thromb Hemost 2010;36:537-49.
15. Ehrenreich H, Weissenborn K, Prange H, et al EPO Stroke Trial Group. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009;40:e647-56.
16. Tang YD, Rinder HM, Katz SD. Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: results of a double-blind, placebo-controlled randomized trial. Am Heart J 2007;154:494.e1-7.
17. Schroeder AP, Houlind K, Pederson EM, et al. Serial magnetic resonance imaging of global and regional left ventricular remodelling during 1 year after acute myocardial infarction. Cardiology 2001;96:106-14. (Pubitemid 33153179)
18. Liem A, Van de Woestijne AP, Bruijns E, et al. Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study. Int J Cardiol 2007;131:285-7.
19. Depping R, Kawakami K, Ocker H, et al. Expression of the erythropoietin receptor in human heart. J Thorac Cardiovasc Surg 2005;130:877-8.
20. Olea FD, Janavel GV, De Lorenzi A, et al. High-dose erythropoietin has no long-term protective effects in sheep with reperfused myocardial infarction. J Cardiovasc Pharmacol 2006;47:736-41. (Pubitemid 44305246)
21. Toma C, Letts DP, Tanabe M, et al. Positive effect of darbepoetin on peri-infarction remodeling in a porcine model of myocardial ischemia- reperfusion. J Mol Cell Cardiol 2007;43:130-6. (Pubitemid 47069386)
22. Binbrek AS, Rao NS, Al Khaja N, et al. Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. Am J Cardiol 2009;104:1035-40.
23. Ferrario M, Arbustini E, Massa M, et al. High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study. Int J Cardiol 2011;147:124-31.
24. Ozawa T, Toba K, Suzuki H, et al EPO/AMI-I Pilot Study Researchers. Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 study. Circ J 2010;74:1415-23.
25. Ott I, Schulz S, Mehilli J, et al; REVIVAL-3 Study Investigators. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv 2010;3:408-13.
26. Voors AA, Belonje AM, Zijlstra F, et al HEBE III Investigators. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 2010;31:2593-600.
27. Mocini D, Muso P, Guendouz E, et al. Endogenous erythropoietin and a single bolus of 40,000 IU of epoetin a do not protect the heart from ischaemia-reperfusion injury during extracorporeal circulation for cardiac surgery. Perfusion 2008;23:187-92.
28. Ludman AJ, Yellon DM, Hausenloy DJ. Cardiac preconditioning for ischaemia: lost in translation. Dis Model Mech 2010;3:35-8.
29. Swift S, Ellison AR, Kassner P, et al. Absence of functional EpoR expression in human tumor cell lines. Blood 2010;115:4254-63.
30. Ghezzi P, Bernaudinb M, Bianchic R, et al. Erythropoietin: not just about erythropoiesis. Lancet 2010;375:2142.